Working With Us
We offer the potential for rapid advancement and value creation for your molecules with:
- Our team of proven drug development experts
Single-minded focus on rapidly achieving clinically meaningful endpoints
Full and separate funding for each program
Flexible, fast and creative approach to transactions
Our Portfolio Strategy
We are assembling a carefully constructed portfolio of clinical candidates across a broad array of mechanisms and therapeutic targets.
Ultimately, we will license or sell those programs that reach clinical proof of concept in order to create value for our company and our partners. We are:
- Seeking late preclinical stage through early Phase 2 programs
- Data-driven, and require a thorough understanding of the biology, mechanism, and potential therapeutic differentiation before committing to a program
- Rigorous and objective in our approach to drug development, incorporating interim analyses and milestones in order to de-risk our investments before major capital commitments are made
Our Flexible Partnering Model
Our strong capital base and unique long-term investment cycle allow us to be flexible and creative in our deal structure and financing.
Our expertise and operating flexibility means that we can thoroughly assess any development opportunity efficiently and be very responsive to potential partners.